Oncology Decision Support Platform

Where patient voice meets clinical evidence

PharmASSIST gives oncology patients a structured way to share what matters to them — and gives clinicians a scannable summary before they walk in the room.

Explore Our Tools → Get In Touch
5.6×
increase in treatment preparedness with Shared Decision-Making
1 in 3
cancer patients get a different decision role than they wanted
15 min
is all a community oncologist has per visit
PharmASSIST — patient survey and clinician summary
Clinically Reviewed By
HOPA — Hematology/Oncology Pharmacy Association
Patient Advocacy Org
Academic Partner
Clinical Reviewer
Why It Matters

The evidence is clear. The gap is real.

Shared Decision-Making improves outcomes across every domain that matters in oncology — yet it rarely happens in practice.

↑
Satisfaction & Knowledge
Patients who experienced SDM consistently rated their care as excellent and reported significantly better understanding of their treatment options.
↓
Decisional Conflict & Regret
SDM produces measurable reductions in uncertainty and regret — outcomes that matter deeply when treatment decisions are high-stakes and often irreversible.
↑
Quality of Life & Adherence
Cancer patients with active involvement in decisions reported higher QoL, better treatment adherence, and less distress than those with passive roles.
5.6×
Greater treatment preparedness
SDM predicted a 5.6-fold increase in feeling prepared for treatment decisions compared to provider-led decisions.
~40%
Biomarker testing gap
Of newly diagnosed patients with NSCLC don't receive comprehensive biomarker testing before starting treatment.
Our Tools

Decision support across oncology

Each module is built for a specific disease state and treatment decision point. New modules launch as clinical need is validated.

Lung Cancer
Live
Biomarker testing gaps and first-line treatment decisions for NSCLC and SCLC.
NSCLC — EGFR Track
● Live
SCLC
● Live
NSCLC — ALK Track
Coming soon
NSCLC — KRAS G12C
Coming soon
Launch NSCLC — EGFR →
Breast Cancer
Coming Soon
HER2, HR+, and triple-negative decision support covering biomarker testing and treatment preferences.
HER2+ Track
Coming soon
HR+ / HER2- Track
Coming soon
Triple Negative Track
Coming soon
In Development
Colorectal Cancer
Coming Soon
RAS/RAF testing gaps, MSI-H identification, and first-line treatment decisions for metastatic CRC.
RAS/RAF Wild-Type
Coming soon
MSI-H / dMMR Track
Coming soon
BRAF V600E Track
Coming soon
In Development
Bladder Cancer
Coming Soon
PD-L1 testing, FGFR alteration identification, and treatment decision support for metastatic urothelial carcinoma.
Metastatic Urothelial
Coming soon
FGFR Track
Coming soon
In Development
Prostate Cancer
Coming Soon
BRCA1/2 and HRR testing, AR pathway decision support for metastatic castration-resistant disease.
mCRPC — HRR Track
Coming soon
mCSPC Track
Coming soon
In Development
Hematologic Cancers
Coming Soon
Mutation testing and treatment decision support for CLL, AML, and multiple myeloma.
CLL / SLL Track
Coming soon
AML Track
Coming soon
Multiple Myeloma
Coming soon
In Development
Get In Touch

Bring PharmASSIST to your patients

Whether you're a clinician, patient advocate, researcher, or institution — we'd like to hear from you.

We respond within 2 business days. Your information is never shared.